Mary Ellen Turner, M.D., M.P.H., is our Senior Vice President, Pharmacovigilance and Corporate Safety Officer and has been at Acadia since May 2016.
Dr. Turner brings to Acadia nearly two decades of experience in clinical safety pharmacovigilance for marketed and investigational products in the pharmaceutical industry, as well as 15 years of experience in direct patient care as a pediatric nephrologist. Dr. Turner joined Acadia from Jazz Pharmaceuticals plc, where she served as Vice President and Global Head, Drug Safety & Pharmacovigilance and R&D Quality Assurance.
Before that, she provided senior-level consulting services in pharmacovigilance, risk management, benefit risk assessment and process improvement for a variety of pharmaceutical companies. Earlier, Dr. Turner served as Corporate Safety Officer and Vice President at Cephalon, Inc. and spent 12 years at Wyeth Research (now Pfizer) in a series of increasingly responsible roles in global safety, surveillance and epidemiology, culminating in the position of Vice President, Risk Management.
Dr. Turner earned her B.S. in Biology from St. Joseph’s University, her M.D. from Georgetown University School of Medicine, and her M.P.H. with a concentration in Epidemiology from George Washington University School of Public Health.